Chen Chun-Chao, Chang Che-Kai, Chiu Chun-Chih, Yang Tsung-Yeh, Hao Wen-Rui, Lin Cheng-Hsin, Fang Yu-Ann, Jian William, Hsu Min-Huei, Yang Tsung-Lin, Liu Ju-Chi, Hsiu Hsin
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.
Taipei Heart Institute, Taipei Medical University, Taipei 110, Taiwan.
J Clin Med. 2022 Oct 17;11(20):6119. doi: 10.3390/jcm11206119.
Various adverse events and complications have been attributed to COVID-19 (coronavirus disease 2019) vaccinations, which can affect the cardiovascular system, with conditions such as myocarditis, thrombosis, and ischemia. The aim of this study was to combine noninvasive pulse measurements and frequency domain analysis to determine if the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) vaccination and its accompanying cardiovascular side effects will induce changes in arterial pulse transmission and waveform. Radial blood pressure waveform and photoplethysmography signals were measured noninvasively for 1 min in 112 subjects who visited Shuang-Ho Hospital for a BNT162b2 vaccination. Based on side effects, each subject was assigned to Group N (no side effects), Group CV (cardiac or vascular side effects), Group C (cardiac side effects only), or Group V (vascular side effects only). Two classification methods were used: (1) machine-learning (ML) analysis using 40 harmonic pulse indices (amplitude proportions, phase angles, and their variability indices) as features, and (2) a pulse-variability score analysis developed in the present study. Significant effects on the pulse harmonic indices were noted in Group V following vaccination. ML and pulse-variability score analyses provided acceptable AUCs (0.67 and 0.80, respectively) and hence can aid discriminations among subjects with cardiovascular side effects. When excluding ambiguous data points, the AUC of the score analysis further improved to 0.94 (with an adopted proportion of around 64.1%) for vascular side effects. The present findings may help to facilitate a time-saving and easy-to-use method for detecting changes in the vascular properties associated with the cardiovascular side effects following BNT162b2 vaccination.
多种不良事件和并发症被认为与2019冠状病毒病（COVID-19）疫苗接种有关，这些事件和并发症可能会影响心血管系统，出现心肌炎、血栓形成和局部缺血等病症。本研究的目的是结合无创脉搏测量和频域分析，以确定辉瑞-BioNTech新冠疫苗（BNT162b2）接种及其伴随的心血管副作用是否会引起动脉脉搏传输和波形的变化。对前往双和医院接种BNT162b2疫苗的112名受试者进行了1分钟的无创桡动脉血压波形和光电容积脉搏波信号测量。根据副作用情况，将每位受试者分为N组（无副作用）、CV组（心脏或血管副作用）、C组（仅心脏副作用）或V组（仅血管副作用）。使用了两种分类方法：（1）以40个谐波脉搏指数（振幅比例、相位角及其变异性指数）为特征的机器学习（ML）分析，以及（2）本研究开发的脉搏变异性评分分析。接种疫苗后，V组的脉搏谐波指数有显著变化。ML分析和脉搏变异性评分分析的受试者工作特征曲线下面积（AUC）均可接受（分别为0.67和0.80），因此有助于区分有心血管副作用的受试者。排除模糊数据点后，评分分析的AUC对血管副作用进一步提高至0.94（采用比例约为64.1%）。本研究结果可能有助于促成一种省时且易用的方法，用于检测与BNT162b2疫苗接种后心血管副作用相关的血管特性变化。
